BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs | BioSpace

After its Biologics License Application was rejected by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.

Read the full article here

Related Articles